Zepbound vs Wegovy: Branded GLP-1 Comparison

A branded-product comparison of Zepbound (Eli Lilly) and Wegovy (Novo Nordisk), the two FDA-approved GLP-1 medications for chronic weight management. Covers manufacturer, approval timeline, savings programs, LillyDirect direct-to-consumer pharmacy, vial vs pen presentations, supply history, and insurance coverage realities — distinct from the mechanism-level tirzepatide vs semaglutide comparison.

Last updated: 2026-05-14

Property	Tirzepatide	Semaglutide
Evidence Level	Level A	Level A
Regulatory Status	FDA ApprovedFDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity.	FDA ApprovedFDA-approved December 2017 (Ozempic) for type 2 diabetes; FDA-approved June 2021 (Wegovy, 2.4 mg) for chronic weight management; FDA-approved September 2019 (Rybelsus, oral) for type 2 diabetes.
Category	Weight Management	Weight Management
Administration	Injectable	Injectable, Oral
Onset Time	Appetite suppression onset within days to weeks; peak weight loss at 36–72 weeks	Appetite suppression onset within days to weeks; peak weight loss at 52–68 weeks
Half-Life	Approximately 5 days (once-weekly dosing)	Approximately 7 days (once-weekly injectable dosing)
Key Mechanism	Tirzepatide's metabolic effects arise from simultaneous activation of two distinct incretin hormone receptors: GLP...	Semaglutide activates the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, brain, gut, heart, ...

Tirzepatide

Evidence Level: Level A
Regulatory Status: FDA ApprovedFDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity.
Category: Weight Management
Administration: Injectable
Onset Time: Appetite suppression onset within days to weeks; peak weight loss at 36–72 weeks
Half-Life: Approximately 5 days (once-weekly dosing)
Key Mechanism: Tirzepatide's metabolic effects arise from simultaneous activation of two distinct incretin hormone receptors: GLP...

Semaglutide

Evidence Level: Level A
Regulatory Status: FDA ApprovedFDA-approved December 2017 (Ozempic) for type 2 diabetes; FDA-approved June 2021 (Wegovy, 2.4 mg) for chronic weight management; FDA-approved September 2019 (Rybelsus, oral) for type 2 diabetes.
Category: Weight Management
Administration: Injectable, Oral
Onset Time: Appetite suppression onset within days to weeks; peak weight loss at 52–68 weeks
Half-Life: Approximately 7 days (once-weekly injectable dosing)
Key Mechanism: Semaglutide activates the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, brain, gut, heart, ...

Key Differences

Zepbound and Wegovy are both FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Zepbound (tirzepatide) is manufactured by Eli Lilly; Wegovy (semaglutide 2.4 mg) is manufactured by Novo Nordisk. The two products differ less in their indication than in how they reach patients — through different manufacturer access programs, distribution channels, formulary positions, and presentation formats. This page focuses on those branded-product differences. For the active-ingredient comparison (mechanism, head-to-head trials, cardiovascular outcomes), see Tirzepatide vs Semaglutide.

Manufacturer and Brand Family

Zepbound is Eli Lilly's brand for tirzepatide indicated for chronic weight management. The same molecule is marketed as Mounjaro for type 2 diabetes. Wegovy is Novo Nordisk's brand for semaglutide 2.4 mg indicated for chronic weight management. The same molecule, at lower doses, is marketed as Ozempic for type 2 diabetes and Rybelsus as an oral tablet for type 2 diabetes. Confusion between the obesity brand and the diabetes brand of the same molecule is common in clinical practice.

FDA Approval Timeline

Wegovy was approved by the FDA on June 4, 2021 for chronic weight management in adults with obesity or overweight with a weight-related condition. In March 2024 the FDA expanded Wegovy's label to include reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity — the first obesity drug with a CV-outcomes indication. Wegovy was also approved for adolescents 12 and older in December 2022.

Zepbound was approved on November 8, 2023 for chronic weight management in adults with obesity or overweight with a weight-related condition. In December 2024 the FDA approved an additional Zepbound indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA program. As of mid-2025, a tirzepatide cardiovascular outcomes indication has not been approved; SURPASS-CVOT topline results have been reported but the full obesity-population MACE data set (SURMOUNT-MMO) is still being evaluated.

Manufacturer Savings Programs

Both manufacturers operate brand-specific savings cards for commercially insured patients. Eligibility, copay reductions, and monthly caps change frequently — verify current terms on the manufacturer's official site before relying on any figure.

Zepbound Savings Card (Lilly): Reduces out-of-pocket cost for commercially insured patients with covered prescriptions; a separate program structure applies when Zepbound is not covered by the patient's insurance. Patients on Medicare, Medicaid, or other federal/state programs are generally not eligible for manufacturer copay cards under federal anti-kickback rules.
Mounjaro Savings Card (Lilly): A parallel program for the diabetes indication of the same molecule. The eligibility logic differs from Zepbound's program and has historically been narrower around use for weight management.
Wegovy Savings Card (Novo Nordisk): Reduces out-of-pocket cost for commercially insured patients with covered prescriptions, with a separate cash-pay program tier for patients without coverage. Same federal-program exclusions apply.

The practical effect: most commercially insured patients with prior authorization pay a reduced copay through the manufacturer card. Patients on Medicare or Medicaid pay the unreduced cash price unless their plan happens to cover the medication, which historically has been rare for obesity.

LillyDirect: Vertical Integration That Novo Doesn't Match

Eli Lilly launched LillyDirect in early 2024 as a direct-to-consumer fulfillment channel for several Lilly medications including Zepbound. Through LillyDirect, eligible patients can receive a telehealth consultation through an independent partner, get a prescription if appropriate, and have the medication shipped from a Lilly-affiliated pharmacy. Lilly also introduced single-dose vial presentations of Zepbound at a lower cash price than the autoinjector pens, sold primarily through LillyDirect.

Novo Nordisk does not operate a comparable direct-to-consumer pharmacy as of mid-2025. Wegovy continues to be distributed through traditional pharmacy channels, supported by the Wegovy savings card program and a separate cash-pay tier. Novo has expanded its NovoCare Pharmacy initiative, but the scope and integration differ from LillyDirect.

Vial vs Pen Presentations

Zepbound is available as both single-dose autoinjector pens (the original presentation) and single-dose vials (introduced in 2024, drawn up with a separate syringe). The vials are sold at a lower cash list price than the pens. As of mid-2025, Lilly's stated cash prices for the lower-dose vials sold through LillyDirect have ranged from approximately $349 to $549 per month depending on dose. These figures change; verify on lilly.com.

Wegovy is available primarily as single-dose autoinjector pens. Novo Nordisk introduced lower-priced cash-pay options through expanded NovoCare programs in 2025, with reported cash list prices for Wegovy lower than the retail price of approximately $1,349 per month. Single-dose vial presentations of Wegovy 2.4 mg comparable to Zepbound's vial channel are not as broadly available; verify current presentation options through Novo Nordisk's official channels.

Supply and Shortage History

Both Zepbound and Wegovy faced significant supply constraints across 2023 and 2024 driven by demand outpacing manufacturing capacity. During these shortages, the FDA Drug Shortage list designation enabled compounding pharmacies to legally compound tirzepatide and semaglutide under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. Both drugs are off the formal FDA shortage list as of mid-2025, which substantially restricts the legal basis for compounded versions, though enforcement and litigation have continued through 2025.

Insurance Coverage Realities

Coverage for both products depends heavily on the insurance plan and the indication being treated.

Commercial insurance for obesity: Most commercial plans cover obesity-indication GLP-1 medications only with prior authorization, often requiring documented BMI thresholds, comorbidities, prior weight-loss attempts, and ongoing weight-loss progress at refill. Both Zepbound and Wegovy face similar PA requirements, though formulary placement varies.
Medicare: Historically excluded weight-loss medications by statute (Section 1860D-2(e)(2)(A) of the Social Security Act). The March 2024 Wegovy CV-outcomes indication created a pathway for Medicare Part D coverage of Wegovy specifically for cardiovascular risk reduction in eligible patients with established CVD and obesity — not for weight loss as a standalone indication. Legislative efforts to broaden Medicare coverage of obesity treatments have been introduced repeatedly; as of mid-2025 broad coverage for weight loss alone has not been enacted.
Medicaid: State-by-state coverage decisions; most states do not cover obesity medications, though a growing minority do.
Type 2 diabetes: Both Mounjaro (tirzepatide for T2D) and Ozempic (semaglutide for T2D) have substantially broader formulary coverage when prescribed for type 2 diabetes than their obesity counterparts.

Patient Assistance for the Uninsured

Both manufacturers operate patient assistance programs (PAPs) for low-income, uninsured patients who meet income and clinical criteria. Lilly Cares covers Zepbound and other Lilly products for qualifying applicants. Novo Nordisk Patient Assistance Program covers Wegovy and other Novo products similarly. These programs are separate from the commercial savings cards and have stricter eligibility thresholds.

Which Is Better For...?

Tirzepatide

Patients who want the lowest cash-pay option — Lilly's single-dose vials of Zepbound sold through LillyDirect have been priced meaningfully below traditional retail pen pricing, and the LillyDirect telehealth-to-pharmacy channel reduces friction for patients without insurance coverage for obesity treatment.

Tirzepatide

Patients eligible for the recently approved obstructive sleep apnea indication — Zepbound is the only GLP-1 with an FDA-approved indication for moderate-to-severe OSA in adults with obesity (approved December 2024), which may unlock insurance coverage pathways not available under an obesity-only indication.

Semaglutide

Patients with established cardiovascular disease who may qualify for Medicare Part D coverage — Wegovy's March 2024 cardiovascular risk reduction indication created a pathway for Medicare coverage in eligible patients with CVD and obesity, a pathway Zepbound does not currently have.

Semaglutide

Adolescents 12 and older with obesity — Wegovy was approved for adolescent use in December 2022, while Zepbound's approved population is adults. For pediatric or adolescent prescribing, Wegovy is currently the only FDA-approved option in the GLP-1 class for chronic weight management.

Semaglutide

Patients with longer-established formulary coverage — Wegovy launched in 2021 and has had more time to negotiate formulary positions across commercial payers than Zepbound (launched late 2023), which can translate to easier prior authorization and lower out-of-pocket costs depending on the specific plan.

Frequently Asked Questions

Are Zepbound and Wegovy the same drug?

No. Zepbound contains tirzepatide, a dual GLP-1/GIP receptor agonist made by Eli Lilly. Wegovy contains semaglutide, a selective GLP-1 receptor agonist made by Novo Nordisk. They are different molecules with different receptor pharmacology, made by different companies. They share the same FDA-approved indication for chronic weight management, which is the source of much of the confusion. For mechanism and clinical-trial comparisons see the tirzepatide vs semaglutide page.

Which costs less out of pocket, Zepbound or Wegovy?

It depends on insurance status and which presentation is purchased. For commercially insured patients with covered prescriptions, the manufacturer savings cards from both companies reduce out-of-pocket cost to a similar range, though specific copay terms differ. For cash-pay patients without insurance, Lilly's single-dose vial presentations of Zepbound sold through LillyDirect have generally been priced below Wegovy's pen presentations, though Novo Nordisk has introduced lower-priced cash-pay options in 2025 that have narrowed the gap. Verify current cash prices directly on lilly.com and novonordisk-us.com before making a decision based on price.

What is LillyDirect and does Novo Nordisk have one?

LillyDirect is Eli Lilly's direct-to-consumer channel launched in early 2024. It connects patients with independent telehealth providers and ships eligible medications, including Zepbound, from a Lilly-affiliated pharmacy. Novo Nordisk operates the NovoCare Pharmacy initiative and various patient-support programs, but as of mid-2025 does not have a comparable vertically integrated telehealth-to-fulfillment channel for Wegovy.

Can Medicare cover Wegovy or Zepbound?

Historically Medicare Part D has been prohibited by statute from covering medications used for weight loss. The March 2024 Wegovy cardiovascular-risk-reduction approval created a pathway for Medicare Part D plans to cover Wegovy specifically for CV risk reduction in eligible patients with established CVD and obesity, but not for weight loss as a standalone indication. Zepbound does not currently have an approved CV-outcomes indication, which limits its Medicare coverage. Legislative changes to broaden Medicare obesity coverage have been introduced repeatedly; verify current Medicare policy at medicare.gov.

Are Zepbound and Wegovy still on the FDA drug shortage list?

No. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. Both products are off the formal FDA shortage list as of mid-2025. This is important because under FDA shortage status, section 503A and 503B compounding pharmacies could legally compound the active ingredients under specific conditions; with the shortages resolved, the legal basis for most compounded tirzepatide and semaglutide has been substantially restricted, though related enforcement and litigation has continued through 2025.

What is the difference between a vial and a pen for these medications?

Pen presentations (autoinjectors) are pre-loaded single-use devices that automate the injection — the patient removes a cap, presses the device against the skin, and the device delivers a fixed dose. Vial presentations are small glass vials of the same medication; the patient draws the dose into a separate syringe and injects manually. Vials require an additional step and a syringe, but Lilly's vial presentations of Zepbound have been priced lower than the pens, which is the main reason patients choose them. Wegovy is primarily distributed in pen presentations; vial availability is more limited.

Does insurance cover Zepbound or Wegovy for weight loss?

Most commercial insurance plans cover one or both medications for chronic weight management with prior authorization, but coverage is highly variable by plan and by employer. Common requirements include documented BMI thresholds, weight-related comorbidities, prior weight-loss attempts, and ongoing measurable weight loss at refill. Formulary position changes year to year — many plans favor one brand or move them to higher tiers. Confirm coverage with the specific insurance plan before assuming either is covered, and ask whether prior authorization is required.

What happens if the patient is uninsured and can't afford either?

Both manufacturers operate patient assistance programs for low-income, uninsured patients who meet income and clinical criteria. Lilly Cares covers Zepbound; the Novo Nordisk Patient Assistance Program covers Wegovy. These programs typically require an application with documentation of income and insurance status, and approval is not guaranteed. They are separate from the commercial savings cards. Patients should also explore whether their state Medicaid program covers obesity medications and whether community health centers or sliding-scale clinics may offer access.

Read Full Profiles

Tirzepatide Semaglutide